Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs Western Alliance Bancorporation — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.5 (market cap $2.27B), while Western Alliance Bancorporation trades at $74.41 (market cap $8.24B). The key difference: Western Alliance Bancorporation is far larger — about 3.6× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Western Alliance Bancorporation pays a 2.23% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| SLS | WAL | |
|---|---|---|
Market Cap | $2.27B | $8.24B |
Volume | 4,179,659 | 1,387,161 |
Sector | Health | Financials |
52-Week High | $15.46 | $96.08 |
52-Week Low | $1.39 | $66.70 |
Enterprise Value | $2.14B | $9.76B |
Typical Hold Time | — | 3 Days |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Western Alliance Bancorporation (WAL) trades at $74.22, down 0.17% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 8.52 and net income margin of 25.43%, while recent earnings have mostly beaten expectations. The company launched WA VenueX, an institutional financial platform, signaling innovation in digital banking services. Analyst consensus is strongly bullish with a $84.33 price target, though technical indicators suggest near-term caution.
WAL presents a compelling value opportunity with attractive valuation multiples and solid profitability, but faces headwinds from bearish technical trends and interest rate sensitivity. The stock's upside hinges on continued earnings growth and successful execution of new initiatives like WA VenueX, while regulatory changes and economic conditions remain key risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
